GlassScriptPhysician profile
Samuel Caughron
NPI 1538216353
$620,885.20
in general payments reported to CMS, 2019-2025
21 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180K · 2020: $91K · 2021: $60K · 2022: $83K · 2023: $60K · 2024: $60K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $135K · Consulting Fee: $35K · Travel and Lodging: $34K · Food and Beverage: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,115.00 |
| Consulting Fee | $34,710.50 |
| Travel and Lodging | $34,290.08 |
| Food and Beverage | $3,125.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $251,943.17 | 2019-2025 | Lynparza, Truqap, Enhertu |
| Genentech USA, INC. | $123,799.62 | 2019-2023 | |
| Lilly USA, LLC | $85,781.47 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $78,005.39 | 2019-2025 | Keytruda, Recarbrio, Dificid |
| E.R. Squibb & Sons, L.L.C. | $20,819.56 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14,045.41 | 2021-2022 | |
| Abbvie INC. | $9,988.95 | 2023-2025 | |
| Astrazeneca Uk Limited | $7,982.50 | 2022 | |
| Eli Lilly and Company | $7,187.50 | 2024 | |
| Janssen Biotech, INC. | $5,251.34 | 2025 | Rybrevant, Erleada, Akeega |
| Genzyme Corporation | $3,759.22 | 2023 | |
| Partner Therapeutics, INC. | $3,675.00 | 2025 | Bizengri |
| Roche Diagnostics Corporation | $3,465.00 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $1,860.00 | 2024 | |
| Illumina, INC. | $1,658.50 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,375.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $64.91 | 2023 | |
| Varian Medical Systems, INC. | $17.11 | 2019 | |
| Siemens Medical Solutions USA, INC. | $13.10 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Caughron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.